Advertisement

Current state-of-the-art in plant-based antibody production systems

  • Marcello DoniniEmail author
  • Carla Marusic
Review
  • 107 Downloads

Abstract

Monoclonal antibodies represent the major class of biopharmaceutical products (for therapeutics and diagnostics) with an increasing demand that reaches several tons per year worldwide. Traditional large-scale manufacturing processes are based on stirred tank bioreactors for the growth of Chinese Hamster Ovary cells (CHO) which requires high initial investments and production costs. Therefore, there is an urgent need for alternative production platforms that can at least act as a complement to the over-exploited mammalian fermentation systems. In this perspective, the use of plants for the large-scale production of biopharmaceuticals (‘Molecular farming’) represents an interesting and mature technology that has already proved its benefits in terms of safety, scalability, rapidity and reduced manufacturing costs. Here we discuss the recent advances in the production of monoclonal antibodies (mAbs) in plant-based platforms such as transgenic plants, tissue and cell cultures and transient expression systems.

Keywords

Agroinfiltration Glycosylation mAb Molecular farming Plant expression systems Transient expression 

Notes

References

  1. Boothe J, Nykiforuk C, Shen Y, Zaplachinski S, Szarka S, Kuhlman P, Murray E, Morck D, Moloney MM (2010) Seed-based expression systems for plant molecular farming. Plant Biotechnol J 8:588–606CrossRefGoogle Scholar
  2. Bosch D, Castilho A, Loos A, Schots A, Steinkellner H (2013) N-glycosylation of plant-produced recombinant proteins. Curr Pharm Des 19:5503–5512CrossRefGoogle Scholar
  3. Buyel JF, Twyman RM, Fischer R (2017) Very-large-scale production of antibodies in plants: the biologization of manufacturing. Biotechnol Adv 35:458–465CrossRefGoogle Scholar
  4. Chen Q, Lai H (2015) Gene delivery into plant cells for recombinant protein production. Biomed Res Int 2015:932161Google Scholar
  5. Chen Q, Lai H, Hurtado J, Stahnke J, Leuzinger K, Dent M (2013) Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Adv Tech Biol Med 1:103CrossRefGoogle Scholar
  6. Circelli P, Donini M, Villani ME, Benvenuto E, Marusic C (2010) Efficient Agrobacterium-based transient expression system for the production of biopharmaceuticals in plants. Bioeng Bugs 1:221–224CrossRefGoogle Scholar
  7. Cox KM, Sterling JD, Regan JT, Gasdaska JR et al (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591–1597CrossRefGoogle Scholar
  8. De Muynck B, Navarre C, Boutry M (2010) Production of antibodies in plants: status after twenty years. Plant Biotechnol J 8:529–563CrossRefGoogle Scholar
  9. Decker EL, Parsons J, Reski R (2014) Glyco-engineering for biopharmaceutical production in moss bioreactors. Front Plant Sci 5:346CrossRefGoogle Scholar
  10. Doron L, Segal N, Shapira M (2016) Transgene expression in microalgae-from tools to applications. Front Plant Sci 7:505CrossRefGoogle Scholar
  11. Drake PMW, Szeto TH, Paul MJ, Teh AY-H, Ma JK-C (2017) Recombinant biologic products versus nutraceuticals from plants - a regulatory choice? Br J Clin Pharmacol 83:82–87CrossRefGoogle Scholar
  12. Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7:9–14CrossRefGoogle Scholar
  13. Fischer R, Vasilev N, Twyman RM, Schillberg S (2015) High-value products from plants: the challenges of process optimization. Curr Opin Biotechnol 32:156–162CrossRefGoogle Scholar
  14. Gavilondo J V, Larrick JW (2000) Antibody engineering at the millennium. BioTechniques 29: 128–32, 134–6, 138 passimGoogle Scholar
  15. Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, Klimyuk V, Gleba Y (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103:14701–14706CrossRefGoogle Scholar
  16. Gleba Y, Klimyuk V, Marillonnet S (2007) Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 18:134–141CrossRefGoogle Scholar
  17. Häkkinen ST, Raven N, Henquet M, Laukkanen M-L et al (2014) Molecular farming in tobacco hairy roots by triggering the secretion of a pharmaceutical antibody. Biotechnol Bioeng 111:336–346CrossRefGoogle Scholar
  18. Hanania U, Ariel T, Tekoah Y, Fux L et al (2017) Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins. Plant Biotechnol J 15:1120–1129CrossRefGoogle Scholar
  19. Hempel F, Maier UG (2012) An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency. Microb Cell Factories 11:126CrossRefGoogle Scholar
  20. Hendin HE, Pillet S, Lara AN, Wu C-Y, Charland N, Landry N, Ward BJ (2017) Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. Vaccine 35:2592–2599CrossRefGoogle Scholar
  21. Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76–78CrossRefGoogle Scholar
  22. Holtz BR, Berquist BR, Bennett LD, Kommineni VJM, Munigunti RK, White EL, Wilkerson DC, Wong K-YI, Ly LH, Marcel S (2015) Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol J 13:1180–1190CrossRefGoogle Scholar
  23. Jansing J, Sack M, Augustine SM, Fischer R, Bortesi L (2018) CRISPR/Cas9-mediated knockout of six glycosyltransferase genes in Nicotiana benthamiana for the production of recombinant proteins lacking β-1,2-xylose and core α-1,3-fucose. Plant Biotechnol J.  https://doi.org/10.1111/pbi.12981 Google Scholar
  24. Jin C, Altmann F, Strasser R, Mach L, Schähs M, Kunert R, Rademacher T, Glössl J, Steinkellner H (2008) A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 18:235–241CrossRefGoogle Scholar
  25. Kelley B (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 1:443–452CrossRefGoogle Scholar
  26. Kircheis R, Halanek N, Koller I, Jost W, Schuster M, Gorr G, Hajszan K, Nechansky A (2012) Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. mAbs 4:532–541CrossRefGoogle Scholar
  27. Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, Ruderfer I, Aviezer D, Shaaltiel Y (2015) Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metabol 114:259–267CrossRefGoogle Scholar
  28. Klimyuk V, Pogue G, Herz S, Butler J, Haydon H (2014) Production of recombinant antigens and antibodies in nicotiana benthamiana using ‘magnifection’ technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol 375:127–154Google Scholar
  29. Komarova TV, Baschieri S, Donini M, Marusic C, Benvenuto E, Dorokhov YL (2010) Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines 9:859–876CrossRefGoogle Scholar
  30. Kopertekh L, Schiemann J (2017) Transient production of recombinant pharmaceutical proteins in plants: evolution and perspectives. Curr Med Chem.  https://doi.org/10.2174/0929867324666170718114724 Google Scholar
  31. Lico C, Chen Q, Santi L (2008) Viral vectors for production of recombinant proteins in plants. J Cell Physiol 216:366–377CrossRefGoogle Scholar
  32. Lim JAC, Patkar A, McDonagh G, Sinclair A, Lucy P (2010) Modeling bioprocess cost: process economic benefits of expression technology based on Pseudomonas fluorescens. BioProcess Int 8:62–70Google Scholar
  33. Lomonossoff GP, D’Aoust M-A (2016) Plant-produced biopharmaceuticals: a case of technical developments driving clinical deployment. Science (New York, N.Y.) 353:1237–1240CrossRefGoogle Scholar
  34. Lonoce C, Salem R, Marusic C, Jutras PV, Scaloni A, Salzano AM, Lucretti S, Steinkellner H, Benvenuto E, Donini M (2016) Production of a tumour-targeting antibody with a human-compatible glycosylation profile in N. benthamiana hairy root cultures. Biotechnol J 11:1209–1220CrossRefGoogle Scholar
  35. Lonoce C, Marusic C, Morrocchi E, Salzano AM, Scaloni A, Novelli F, Pioli C, Feeney M, Frigerio L, Donini M (2018) Enhancing the secretion of a glyco-engineered anti-CD20 scFv-Fc antibody in hairy root cultures. Biotechnol J.  https://doi.org/10.1002/biot.201800081 Google Scholar
  36. Ma JK, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, van Dolleweerd C, Mostov K, Lehner T (1995) Generation and assembly of secretory antibodies in plants. Science (New York, N.Y.) 268:716–719CrossRefGoogle Scholar
  37. Ma JK-C, Drossard J, Lewis D, Altmann F et al (2015) Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J 13:1106–1120CrossRefGoogle Scholar
  38. Magy B, Tollet J, Laterre R, Boutry M, Navarre C (2014) Accumulation of secreted antibodies in plant cell cultures varies according to the isotype, host species and culture conditions. Plant Biotechnol J 12:457–467CrossRefGoogle Scholar
  39. Marusic C, Pioli C, Stelter S, Novelli F, Lonoce C, Morrocchi E, Benvenuto E, Salzano AM, Scaloni A, Donini M (2018) N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions. Biotechnol Bioeng 115:565–576CrossRefGoogle Scholar
  40. Mathieu-Rivet E, Kiefer-Meyer M-C, Vanier G, Ovide C, Burel C, Lerouge P, Bardor M (2014) Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals. Front Plant Sci 5:359CrossRefGoogle Scholar
  41. Mayfield SP, Franklin SE, Lerner RA (2003) Expression and assembly of a fully active antibody in algae. Proc Natl Acad Sci USA 100:438–442CrossRefGoogle Scholar
  42. Mehrotra S, Srivastava V, Rahman LU, Kukreja AK (2015) Hairy root biotechnology—indicative timeline to understand missing links and future outlook. Protoplasma 252:1189–1201CrossRefGoogle Scholar
  43. Mercx S, Smargiasso N, Chaumont F, De Pauw E, Boutry M, Navarre C (2017) Inactivation of the β(1,2)-xylosyltransferase and the α(1,3)-fucosyltransferase genes in Nicotiana tabacum BY-2 Cells by a Multiplex CRISPR/cas9 strategy results in glycoproteins without plant-specific glycans. Front Plant Sci 8:403CrossRefGoogle Scholar
  44. Montero-Morales L, Steinkellner H (2018) Advanced plant-based glycan engineering. Front Bioeng Biotechnol 6:81CrossRefGoogle Scholar
  45. Mor TS (2015) Molecular pharming’s foot in the FDA’s door: protalix’s trailblazing story. Biotechnol Lett 37:2147–2150CrossRefGoogle Scholar
  46. Navarre C, Smargiasso N, Duvivier L, Nader J, Far J, De Pauw E, Boutry M (2017) N-Glycosylation of an IgG antibody secreted by Nicotiana tabacum BY-2 cells can be modulated through co-expression of human β-1,4-galactosyltransferase. Transgenic Res 26:375–384CrossRefGoogle Scholar
  47. Pillet S, Aubin É, Trépanier S, Bussière D, Dargis M, Poulin J-F, Yassine-Diab B, Ward BJ, Landry N (2016) A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol (Orlando, Fla.) 168:72–87CrossRefGoogle Scholar
  48. Potvin G, Zhang Z (2010) Strategies for high-level recombinant protein expression in transgenic microalgae: a review. Biotechnol Adv 28:910–918CrossRefGoogle Scholar
  49. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT, Dodd L, Proschan MA, Neaton J et al (2016) A randomized, controlled trial of ZMapp for ebola virus infection. NE ngl J Med 375:1448–1456CrossRefGoogle Scholar
  50. Qiu X, Wong G, Audet J, Bello A et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53CrossRefGoogle Scholar
  51. Rademacher T (2013) Method for the generation and cultivation of a plant cell pack. Patent WO2013/113504Google Scholar
  52. Rademacher T, Sack M, Arcalis E, Stadlmann J et al (2008) Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 6:189–201CrossRefGoogle Scholar
  53. Raven N, Rasche S, Kuehn C, Anderlei T et al (2015) Scaled-up manufacturing of recombinant antibodies produced by plant cells in a 200-L orbitally-shaken disposable bioreactor. Biotechnol Bioeng 112:308–321CrossRefGoogle Scholar
  54. Reski R, Parsons J, Decker EL (2015) Moss-made pharmaceuticals: from bench to bedside. Plant Biotechnol J 13:1191–1198CrossRefGoogle Scholar
  55. Sainsbury F, Sack M, Stadlmann J, Quendler H, Fischer R, Lomonossoff GP (2010) Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS ONE 5:e13976CrossRefGoogle Scholar
  56. Santos RB, Abranches R, Fischer R, Sack M, Holland T (2016) Putting the spotlight back on plant suspension cultures. Front Plant Sci 7:297CrossRefGoogle Scholar
  57. Saxena P, Thuenemann EC, Sainsbury F, Lomonossoff GP (2016) Virus-derived vectors for the expression of multiple proteins in plants. Methods Mol Biol (Clifton, N.J.) 1385:39–54CrossRefGoogle Scholar
  58. Schillberg S, Raven N, Fischer R, Twyman RM, Schiermeyer A (2013) Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr Pharm Des 19:5531–5542CrossRefGoogle Scholar
  59. Shamriz S, Ofoghi H (2016) Outlook in the application of Chlamydomonas reinhardtii chloroplast as a platform for recombinant protein production. Biotechnol Genet Eng Rev 32:92–106CrossRefGoogle Scholar
  60. Shen J-S, Busch A, Day TS, Meng X-L et al (2016) Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metabol Dis 39:293–303CrossRefGoogle Scholar
  61. Sheshukova EV, Komarova TV, Dorokhov YL (2016) Plant factories for the production of monoclonal antibodies. Biochemistry 81:1118–1135Google Scholar
  62. Shukla AA, Wolfe LS, Mostafa SS, Norman C (2017) Evolving trends in mAb production processes. Bioeng Trans Med 2:58–69Google Scholar
  63. Sijmons PC, Dekker BM, Schrammeijer B, Verwoerd TC, van den Elzen PJ, Hoekema A (1990) Production of correctly processed human serum albumin in transgenic plants. Bio/technology (Nature Publishing Company) 8:217–221Google Scholar
  64. Steinkellner H, Castilho A (2015) N-Glyco-engineering in plants: update on strategies and major achievements. Methods Mol Biol (Clifton, N.J.) 1321:195–212CrossRefGoogle Scholar
  65. Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, Glössl J, Weterings K, Pabst M, Steinkellner H (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 6:392–402CrossRefGoogle Scholar
  66. Tekoah Y, Shulman A, Kizhner T, Ruderfer I et al (2015) Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience. Plant Biotechnol J 13:1199–1208CrossRefGoogle Scholar
  67. Tusé D, Ku N, Bendandi M, Becerra C et al (2015) Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma. Biomed Res Int 2015:648143CrossRefGoogle Scholar
  68. Vanier G, Lucas P-L, Loutelier-Bourhis C, Vanier J, Plasson C, Walet-Balieu M-L et al (2017) Heterologous expression of the N-acetylglucosaminyltransferase I dictates a reinvestigation of the N-glycosylation pathway in Chlamydomonas reinhardtii. Sci Rep 7:10156CrossRefGoogle Scholar
  69. Vanier G, Stelter S, Vanier J, Hempel F, Maier UG, Lerouge P, Ma J, Bardor M (2018) Alga-made anti-Hepatitis B antibody binds to human Fcγ receptors. Biotechnol J 13:e1700496CrossRefGoogle Scholar
  70. Vasilev N, Grömping U, Lipperts A, Raven N, Fischer R, Schillberg S (2013) Optimization of BY-2 cell suspension culture medium for the production of a human antibody using a combination of fractional factorial designs and the response surface method. Plant Biotechnol J 11:867–874CrossRefGoogle Scholar
  71. Weintraub JA, Hilton JF, White JM, Hoover CI, Wycoff KL, Yu L, Larrick JW, Featherstone JDB (2005) Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res 39:241–250CrossRefGoogle Scholar
  72. White FF, Taylor BH, Huffman GA, Gordon MP, Nester EW (1985) Molecular and genetic analysis of the transferred DNA regions of the root-inducing plasmid of Agrobacterium rhizogenes. J Bacteriol 164:33–44Google Scholar
  73. Wongsamuth R, Doran PM (1997) Production of monoclonal antibodies by tobacco hairy roots. Biotechnol Bioeng 54:401–415CrossRefGoogle Scholar
  74. Xu J, Zhang N (2014) On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect. Pharm Bioprocess 2:499–518CrossRefGoogle Scholar
  75. Xu J, Dolan MC, Medrano G, Cramer CL, Weathers PJ (2012) Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol Adv 30:1171–1184CrossRefGoogle Scholar
  76. Yao J, Weng Y, Dickey A, Wang KY (2015) Plants as Factories for human pharmaceuticals: applications and challenges. Int J Mol Sci 16:28549–28565CrossRefGoogle Scholar
  77. Yusibov V, Kushnir N, Streatfield SJ (2016) Antibody production in plants and green algae. Annu Rev Plant Biol 67:669–701CrossRefGoogle Scholar
  78. Zischewski J, Sack M, Fischer R (2016) Overcoming low yields of plant-made antibodies by a protein engineering approach. Biotechnol J 11:107–116CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Laboratory of BiotechnologyENEA Casaccia Research CenterRomeItaly

Personalised recommendations